News headlines about Iqvia (NYSE:IQV) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iqvia earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 44.8505166100853 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Quotidian Technical Highlights on Selected Medical Research Stocks — Thermo Fisher Scientific, Agilent Technologies, IQVIA, and Charles River Labs (medindia.net)
- Iqvia Holdings Inc (IQV) Insider Sells $4,690,483.20 in Stock (americanbankingnews.com)
- Commit To Buy IQVIA Holdings At $97.50, Earn 6.8% Annualized Using Options (nasdaq.com)
- Trending Stocks Buzz: Aetna Inc., (NYSE: AET), IQVIA Holdings, Inc., (NYSE: IQV), Drive Shack Inc., (NYSE: DS … – Stocks In The News (press release) (tradingnewsnow.com)
- IQVIA Holdings, Inc. – Value Analysis (NYSE:IQV) : December 4, 2017 (finance.yahoo.com)
IQV has been the topic of several research reports. Argus lifted their price objective on Iqvia from $98.00 to $104.00 and gave the company a “buy” rating in a research report on Monday, September 18th. KeyCorp reaffirmed a “buy” rating and set a $100.00 price objective on shares of Iqvia in a research report on Sunday, September 24th. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $107.00 price target on the stock in a research report on Wednesday, October 11th. BidaskClub cut Iqvia from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 11th. Finally, Stifel Nicolaus raised Iqvia from a “hold” rating to a “buy” rating and boosted their price target for the stock from $92.00 to $128.00 in a research report on Friday, October 27th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Iqvia presently has an average rating of “Buy” and an average target price of $105.23.
Iqvia (NYSE:IQV) traded up $0.01 during trading hours on Wednesday, hitting $101.01. The stock had a trading volume of 920,425 shares, compared to its average volume of 1,502,003. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. The stock has a market cap of $21,316.11, a price-to-earnings ratio of 23.12, a price-to-earnings-growth ratio of 1.66 and a beta of 0.61. Iqvia has a 52-week low of $74.73 and a 52-week high of $110.67.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.14 by $0.05. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. Iqvia’s revenue was up 77.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.00 EPS. research analysts anticipate that Iqvia will post 4.62 earnings per share for the current year.
In other Iqvia news, Director John Connaughton sold 1,030,429 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $94.87, for a total transaction of $97,756,799.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James H. Erlinger III sold 10,000 shares of the stock in a transaction dated Wednesday, September 27th. The shares were sold at an average price of $94.52, for a total transaction of $945,200.00. Following the transaction, the insider now directly owns 27,340 shares of the company’s stock, valued at approximately $2,584,176.80. The disclosure for this sale can be found here. Insiders sold a total of 16,631,093 shares of company stock valued at $1,640,970,687 in the last ninety days. 6.40% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This report was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2017/12/06/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-iqvia-iqv-share-price-updated.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Holdings Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Iqvia Holdings Inc and related companies with MarketBeat.com’s FREE daily email newsletter.